217 related articles for article (PubMed ID: 15886298)
21. Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter.
Yoon JH; Kim JK; Rha GB; Oh M; Park SH; Seong RH; Hong SH; Park SD
Biochem J; 1999 Dec; 344 Pt 2(Pt 2):367-74. PubMed ID: 10567217
[TBL] [Abstract][Full Text] [Related]
22. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
[TBL] [Abstract][Full Text] [Related]
23. Targeting the inverted CCAAT box 2 in the topoisomerase IIalpha promoter by JH-37, an imidazole-pyrrole polyamide hairpin: design, synthesis, molecular biology, and biophysical studies.
Henry JA; Le NM; Nguyen B; Howard CM; Bailey SL; Horick SM; Buchmueller KL; Kotecha M; Hochhauser D; Hartley JA; Wilson WD; Lee M
Biochemistry; 2004 Sep; 43(38):12249-57. PubMed ID: 15379563
[TBL] [Abstract][Full Text] [Related]
24. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
Mo YY; Wang Q; Beck WT
Cancer Res; 1997 Nov; 57(22):5004-8. PubMed ID: 9371492
[TBL] [Abstract][Full Text] [Related]
25. Characterization of promoter elements involved in the down-regulation of topoisomerase IIalpha expression in a drug-resistant cell line.
Saxena D; Yiu GK; Ni X; Huang KC; Mantovani R; Jacquemin-Sablon AG; Ng SW
Gene; 2004 Nov; 342(1):145-55. PubMed ID: 15527974
[TBL] [Abstract][Full Text] [Related]
26. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
27. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
28. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.
Herzog CE; Holmes KA; Tuschong LM; Ganapathi R; Zwelling LA
Cancer Res; 1998 Dec; 58(23):5298-300. PubMed ID: 9850052
[TBL] [Abstract][Full Text] [Related]
29. Somatostatin elevates topoisomerase II alpha and enhances the cytotoxic effect of doxorubicin on gallbladder cancer cells.
Quan ZW; Yue JN; Li JY; Qin YY; Guo RS; Li SG
Chemotherapy; 2008; 54(6):431-7. PubMed ID: 18824850
[TBL] [Abstract][Full Text] [Related]
30. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16.
Zhou RR; Jia SF; Zhou Z; Wang Y; Bucana CD; Kleinerman ES
Cancer Gene Ther; 2002 May; 9(5):407-13. PubMed ID: 11961663
[TBL] [Abstract][Full Text] [Related]
31. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
32. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
33. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical study on topoisomerase IIalpha, Ki-67 and cytokeratin-19 in oral lichen planus lesions.
Mattila R; Alanen K; Syrjänen S
Arch Dermatol Res; 2007 Jan; 298(8):381-8. PubMed ID: 17072627
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
36. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
37. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
[TBL] [Abstract][Full Text] [Related]
38. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Whitacre CM; Zborowska E; Gordon NH; Mackay W; Berger NA
Cancer Res; 1997 Apr; 57(8):1425-8. PubMed ID: 9108439
[TBL] [Abstract][Full Text] [Related]
39. Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients.
Wang YH; Takanashi M; Tsuji K; Tanaka N; Shiseki M; Mori N; Motoji T
Leuk Res; 2009 Jul; 33(7):902-7. PubMed ID: 19185918
[TBL] [Abstract][Full Text] [Related]
40. Dynamics of human DNA topoisomerases IIalpha and IIbeta in living cells.
Christensen MO; Larsen MK; Barthelmes HU; Hock R; Andersen CL; Kjeldsen E; Knudsen BR; Westergaard O; Boege F; Mielke C
J Cell Biol; 2002 Apr; 157(1):31-44. PubMed ID: 11927602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]